This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under CFDA 93.859 Biomedical Research and Research Training program provides $306,860 to Mixedlcmedia LLC, a small disadvantaged business, to develop and evaluate a prototype ultra-low flow liquid chromatography platform based on their proprietary porous layer open-tubular (PLOT) and monolithic nanocolumn technologies. The goal is to create a commercialization-ready LC system that enables deep proteomic...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) provides $295,561 to Biosensing Instrument Inc. to develop a commercial prototype of their Plasmonic Scattering Microscopy (PSM) technology. The PSM system aims to enable high-throughput, label-free quantification of membrane protein binding kinetics on single cells in their native cellular microenvironment. This represents a...
The National Institutes of Health (NIH) National Institute of General Medical Sciences (NIGMS) awarded a $375,000 Project Grant (CFDA 93.859 Biomedical Research and Research Training) to Rowan University to develop a liquid chromatography-mass spectrometry (LC-MS) platform for rapid, real-time monitoring of targeted small molecule metabolites in biological systems. The project aims to create a sensor-like LC-MS system that can simultaneously monitor multiple analytes through miniaturization,...
This $350,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports the development and optimization of a novel, enzyme-based, single-molecule protein sequencing system by Electronic Biosciences, Inc. The objective is to create a rapid, reliable, and cost-effective platform that can accurately sequence proteins, including those with post-translational modifications, through the...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) provides $316,825 in funding to Massmatrix Inc. to advance native mass spectrometry (MS) analysis. The key objectives are to: 1) implement enhanced deconvolution techniques to reduce artifacts and optimize processing speed without sacrificing accuracy; 2) automate spectrum reconstruction for efficient handling of diverse analytical...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) will support a high-risk, high-reward effort to improve the sensitivity and selectivity of laser desorption ionization for mass spectrometry-based proteomics applications. The $247,767 award, effective September 1, 2024 through August 31, 2026, will enable researchers at the University of Notre Dame to develop proof-of-concept experiments...
This $939,086 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) will support research to develop novel mass spectrometry-based approaches for profiling biomolecules, including proteins, lipids, and metabolites, at the single-cell level. The research aims to provide an unprecedented view of cellular regulation from genotype to phenotype by combining these mass spectrometry capabilities with...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training Program (CFDA 93.859), provides $2,297,901 to GMJ Technologies, Inc., a minority-owned small disadvantaged business, to develop a high-resolution native capillary zone electrophoresis system with inline UV and native mass spectrometry capabilities. This innovative analytical technology aims to enhance the characterization and quality control of protein...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) is for the development of advanced mass spectrometry-based proteomics pipelines to improve depth, throughput, and accuracy. The $453,750 award, with a project period from April 16, 2025 to January 31, 2030, will support research at Harvard Medical School to address challenges in sample preparation and data acquisition for proteome-wide protein...
This $600,120 federal Project Grant award from the National Science Foundation (NSF) Biological Sciences program (CFDA 47.074) supports the development of a groundbreaking microfluidic-based weighing instrument capable of measuring mass changes in live single cells with picogram accuracy and millisecond resolution. The Icahn School of Medicine at Mount Sinai, a prominent academic medical research institution, will lead this 4-year research project. The instrument will utilize small pipettes to...
QUANTITATIVE SINGLE CELL MASS SPECTROMETRY FOR SMALL MOLECULES WITH UNPRECEDENTED SENSITIVITY - PROJECT SUMMARY FUNDAMENTAL UNDERSTANDING OF THE DEVELOPMENT OF CELLULAR METABOLIC HETEROGENEITY AND ITS IMPACT ON CELL RESPONSE TO STIMULI HAS RAMIFICATIONS ON NEARLY EVERY ASPECT OF BIOMEDICAL RESEARCH INCLUDING DISEASE DIAGNOSIS, TREATMENT AND PREVENTION. CELLULAR METABOLISM IS NATURALLY HETEROGENEOUS AND PREDICTION OF CELLULAR RESPONSE TO STIMULI WILL DEPEND ON THE DISTRIBUTION OF INTRACELLULAR METABOLITE CONCENTRATIONS ACROSS A CELL POPULATION. HOWEVER, FOR SMALL MOLECULES AND THERAPEUTICS DIRECT EMPIRICAL MEASURE OF INTRACELLULAR CONCENTRATIONS IS RARE, THOUGH MANY DRUGS TARGET INSIDE THE CELL AND REQUIRE REACHING THEIR SITE OF ACTION AT A SPECIFIC CONCENTRATION TO BE EFFECTIVE. THEIR QUANTITATIVE DISTRIBUTION IN A CELL POPULATION IS A KEY, CURRENTLY UNMEASURABLE, VARIABLE TO UNDERSTANDING MANY DRUG'S PHARMACOLOGICAL AND TOXICOLOGICAL EFFECTS. THE BEST WAY TO DECONVOLUTE HETEROGENEOUS CELL RESPONSE IS TO INDIVIDUALLY PROFILE EACH CELL IN THE POPULATION. UNFORTUNATELY, CURRENT SINGLE CELL ANALYSIS APPROACHES FOR MEASURING SMALL MOLECULES LACK A NUMBER OF CRITICAL FEATURES NEEDED TO MAKE ANALYSIS ROUTINE. AN IDEAL SINGLE CELL CHARACTERIZATION METHOD MUST BE QUANTITATIVE, FAST, ROBUST, SENSITIVE, APPLICABLE TO A RANGE OF CELL TYPES AND BE ABLE TO MEASURE A WIDE RANGE OF MOLECULES. THE LACK OF SUCH A SYSTEM RESTRICTS DETAILED INVESTIGATIONS INTO THE FUNDAMENTAL MECHANISMS UNDERPINNING HETEROGENEOUS CELL RESPONSE; FOUNDATIONAL INFORMATION NEEDED FOR ADVANCING DISEASE DIAGNOSIS, TREATMENT AND PREVENTION AS PART OF THE MISSION OF NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES (NIGMS). THE GOAL OF THIS RESEARCH IS TO EVALUATE A HIGH-RISK/HIGH-REWARD APPROACH, PULSED SINGLE CELL MASS SPECTROMETRY (P-SC-MS), A NOVEL CONCEPT OF CAPTURING, LYSING AND ANALYZING SINGLE CELLS WITH SIGNIFICANTLY IMPROVED SENSITIVITY AND THROUGHPUT OVER EXISTING SINGLE CELL ANALYSIS METHODOLOGIES FOR SMALL MOLECULES. OUR APPROACH REQUIRES OVERCOMING HIGH-RISK CHALLENGES IN DROPLET CAPTURE AND CELL LYSIS AT SMALL SCALE AND UNDER A HIGH ELECTRIC FIELD ENVIRONMENT. THIS RISK IS OFFSET BY A CORRESPONDINGLY HIGH REWARD: MASSIVELY INCREASED SENSITIVITY (>50,000X), SINGLE CELL ANALYSIS THROUGHPUT (>6X) AND CELL MEDIA TOLERANCE OVER THE CURRENT STATE-OF- THE-ART. THE PLATFORM IS EASY TO USE AND WILL BE SHOWN TO BE APPLICABLE FOR MANY CELL TYPES THROUGH THREE SPECIFIC AIMS TACKLING THE FEASIBILITY OF THE CONCEPT. SPECIFIC AIM #1: DEMONSTRATE SINGLE CELL DROPLET-ON-DEMAND CAPTURE AND METABOLITE EXTRACTION USING A CUSTOM PULSED-NANOELECTROSPRAY IONIZATION SOURCE. SPECIFIC AIM #2: VALIDATE THE QUANTITATIVE ACCURACY OF P-SC-MS THROUGH MEASURE OF AMIODARONE (AMIO) AND N-DESETHYLAMIODARONE (NDEA) IN SINGLE HEPG2 CELLS. SPECIFIC AIM #3: DEMONSTRATE MEASURE AND COMPARISON OF METABOLITES AND LIPIDS IN HELA, HEPG2, MD-AMB, BT-474 AND OK-F6 CELL LINES IN COMPLEX MEDIA. THE END PRODUCT OF THIS RESEARCH WILL BE A NOVEL, HIGH-IMPACT TECHNOLOGY THAT ENABLES CHEMICAL CHARACTERIZATION OF SMALL MOLECULES FROM SINGLE CELLS WITH A MASSIVE >50,000X IMPROVEMENT IN SENSITIVITY AND 6X IMPROVEMENT IN SPEED OVER CURRENT ART, ENABLING RESOLUTION OF INTRACELLULAR MOLECULAR DISTRIBUTIONS.